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a1-protease inhibitor (Pi) deficiency is associated with a protease–anti-protease imbalance leading to premature
destruction of lung tissue and early emphysema. Little is known about the blood gases of these patients in the
various stages of the disease. The purpose of this study was to evaluate blood gases in patients with a1-Pi deficiency
when patients were at rest and during exercise, and to correlate these with lung function measurements. A total of
369 patients with severe a1-Pi deficiency had pulmonary function test and blood gas analysis, 282 also had blood
gases taken during steady state submaximal exercise testing. Only 21% of the patients had normal blood gases at
rest; 71% had mild hypoxaemia; 8% had severe hypoxaemia. Surprisingly, 61% of the patients with mild lung
disease and a FEV1 of more than 65% predicted were hypoxaemic. During exercise 65% of the patients had a drop
in PO2 of more than 0?40 kPa. FEV1 was a significant predictor for the PO2 values at rest and during exercise.
During exercise the arterial–alveolar gradient increased in about 50% and decreased in 25% of the patients. Many
patients with a1-Pi have blood gas abnormalities. Impaired blood gases in early stages of the disease result in a
discrepancy between lung function parameters and blood gases. FEV1 measurements inadequately capture the
extent of lung disease in patients with a1-Pi deficiency, and both blood gases at rest and during exercise are needed
in the assessment of all stages of the disease.
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Patients with severe a1-protease inhibitor (a1-Pi or a1-anti-
trypsin) deficiency develop emphysema early in life (1). This
is thought to be due to a protease–anti-protease imbalance
which leads to accelerated destruction of matrix proteins
(2–4). Many patients consult physicians because of
symptoms of chronic bronchitis (5–8) and dyspnoea
whether at rest or during exercise (1,9–12). Hence, the
diagnosis of their severe a1-protease inhibitor deficiency is
often delayed and prescribed behaviour changes, particu-
larly smoking cessation, are only then begun in advanced
stages of the disease. In a large survey of 414 a1-Pi
deficiency patients, Stoller (13) found a delay between first
presentation and final diagnosis of 7?2 years, with a
standard deviation of 8?3 years. Forty-four per cent of
patients saw at least three doctors and 13% more than six
doctors before the correct diagnosis was made. One reason
why a1-Pi deficiency is possibly underrecognized is its low
prevalence, 1:2500 in the general Caucasian population
(5,14,15), although incidence may be as high as 2–3% in aReceived 7 April 2000 and accepted in revised form 3 August 2000.
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0954-6111/00/121177+07 $35?00/0selected group of patients with chronic obstructive
pulmonary disease (COPD) (16). This low prevalence in
the general population may result in a low awareness
among primary care providers of a1-Pi deficiency. Other
reasons include a substantial overlap between the symp-
toms of a1-Pi deficiency and those of chronic bronchitis,
smoking-related emphysema and asthma.
Yet another possible cause for the under-recognition of
the disease, however, may be that commonly used para-
meters to evaluate the severity of COPD are less sensitive in
patients with a1-Pi deficiency. Forced expiratory volume
(FEV1) is most often used to assess COPD, with severity of
disease graded according to reduction in FEV1 (17). In
COPD, lung function changes often precede dyspnoea, but
blood gases may be already impaired in early stages of
COPD (18)
Analysis of blood gases at rest and during exercise is well
established as a method to diagnose gas exchange
abnormalities of various pulmonary and non-pulmonary
diseases. The main causes for hypoxaemia are alveolar
hypoventilation, diffusion impairment, ventilation–perfu-
sion mismatch and anatomical arterio-venous shunt. These
causes can be differentiated by blood gas analysis during
exercise (19). To date, no studies have been reported that
correlate blood gas and lung function in patients with a1-Pi
deficiency.# 2000 HARCOURT PUBLISHERS LTD
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blood gas concentrations at rest and during exercise in
patients with severe a1-Pi deficiency are correlated with
severity of disease, as determined by FEV1 measurements.
Methods
Four hundred and forty-three patients with severe a1-Pi
deficiency were included in a drug surveillance study.
Patients received weekly intravenous augmentation therapy
with 60mg kg71 human a1-Pi (Prolastin
1 HS, Bayer,
Leverkusen, Germany). Patients older than 18 years were
included if they had a severe a1-Pi deficiency with either a
proven phenotype PiZZ on isoelectric focusing or plasma
levels of a1-Pi less than 80mgdl
71, as measured by radial
immunodiffusion.
LUNG FUNCTION MEASUREMENTS
Pulmonary function tests (PFTs) were performed within 6
months of beginning augmentation therapy. Flow volume-
loop and whole body plethysmography measurements were
carried out before and after bronchodilation. In each case
the best of three trials was used for further analysis.
Measurements were performed in accordance with ERS
recommendations (20,21). Predicted values were calculated
according to European reference equations (European
Community for Coal and Steel) (21).
Alveolar partial oxygen pressure was calculated accord-
ing to the alveolar air equation:
PAO2 ¼ Fio2  ðPB ÿ PH2OÞ ÿ ðPaCO2=RQÞ
where Fio2 is the inspired oxygen fraction of 0?209; PB the
barometric pressure; PH2O the partial pressure of water at
body temperature (6?27 kPa); PaCO2 the measured partial
pressure of carbon dioxide in the arterialized blood; and
RQ, the respiratory ratio, assumed to be 0?8. The arterial
alveolar gradient (AaDO2) is the difference between the
alveolar partial oxygen pressure and the measured PO2 in
the blood.
BLOOD GASES MEASUREMENTS
As part of the clinical assessment, blood gases at rest, and if
possible during exercise, were measured. For the blood gasTABLE 1. Demographic data of 369 patients with severe a1-Pi d
Total
Age [years] 46?1+8?8
Sex m/f 240/129
BMI [kg/m72] 22?7+3?5
Phenotype PiZZ 338
PiSZ 25
Other or unknown 6
BMI: body mass index; FEV1: forced expiratory volume in 1 sanalysis, a sample of arterialized blood was taken from the
hyperaemic ear lobe. If possible, patients underwent a
symptom-limited submaximal treadmill exercise and an
additional sample of blood was drawn for gas analysis on
completion of the exercise, in the sixth minute. Due to the
wide variation of lung function impairment and dyspnoea
of the patients, no other attempt to standardize the exercise
protocol was made other than to reach a respiratory steady
state. A change of PO2 or PCO2 of more than 0?40 kPa
during exercise was considered as clinically significant.
A total of 443 patients comprised the drug surveillance
study population for intravenous augmentation therapy;
a1-Pi. Three hundred and sixty-nine patients had at least
one pulmonary function test and one blood gas analysis at
rest on the same day within the first 6 months of when their
augmentation therapy began. These patients were included
for further analysis; their demographic data are given in
Table 1. If more than one complete set of data was available
on a patient, the first data set was used in this analysis.
MATHEMATICAL AND STATISTICAL
METHODS
Patients were grouped according to lung function impair-
ment at the first visit after the start of augmentation
therapy: group I had an initial FEV1 of less than 30% of
predicted normal; group II had between 30% and 65%;
group III had greater than 65%. To eliminate the effect of
reversible airway obstruction, this analysis was made for
post-bronchodilator FEV1 only. The range of 4?67–
6?00 kPa (35–45mmHg) was accepted as normal for PCO2
values. Partial oxygen pressures of less than 10 kPa
(75mmHg) were regarded as mild hypoxaemia, and values
less than 7?33 kPa (55mmHg) were viewed as severe
hypoxaemia.
Descriptive data are presented as mean+standard
deviation (SD). To compare blood gas analysis and lung
function parameters, linear regression analysis was per-
formed according to the least squares method and the
correlation coecient calculated. The influence of the
functional groups on the variables was analysed with an
ANOVA test. For the analysis of paired data, a Wilcoxon
matched-pairs signed-rank test was used. To calculate the
discrepancy between the expected and the observed
frequencies, a 2-test was applied. The type I error rate aeficiency (mean+SD)
FEV1 465 FEV1 30–65 FEV1 530
45?2+10?7 47?7+8?8 46?3+8?2
19/12 121/90 100/27
24?9+3?4 22?9+3?5 22?0+3?3
29 196 113
2 14 9
— 1 5
ec.
FIG. 1. Blood gases at rest of 369 patients with a1-Pi
deficiency stratified for impairment of FEV1 (a) PO2 at
rest; (b) AaDO2 at rest; (c) PCO2 at rest.
BLOOD GASES a1-PI DEFICIENCY 1179was fixed to be 0?05 and no adjustment in case of multiple
testing situations were performed. Thus, P-values falling
below this threshold indicate statistical significance on a
comparison-wise level.
Results
BLOOD GAS ANALYSIS AT REST
Mean PO2 at rest was 8?00+9?3 kPa in the 369 patients
tested. The PO2 was significantly lower in patients with
severe emphysema compared to patients with mild or
moderate emphysema (8?7+1?11 vs. 9?42+1?20 and
9?69+1?41 kPa, respectively, P50?001). Only 78 of the
369 patients (21%) had PO2 values at rest of 10?0 kPa or
higher, 262 (71%) had values between 10 and 7?33 kPa, and
the remaining 30 (8%) had PO2 values lower than 7?33 kPa.
The percentage of patients with normal PO2 declined from
39 in group III to nine in group I and the percentage of
patients with severe hypoxaemia increased from three to 13,
respectively, between these same groups. The majority of
patients in all groups had mild hypoxaemia [Fig. 1(a)].
The mean value for AaDO2 was 4?71+1?32 kPa, with
little variation between the groups. Of the total group, only
48 (13%) had normal values of AaDO2 (between 0?67 and
2?67 kPa); all others had increased values for AaDO2. Of the
patients with severe lung function impairment, only five
(4%) had a normal AaDO2 [Fig. 1(b)]. The difference of
AaDO2 between the FEV1 groups did not reach statistical
significance.
The mean PCO2 was 4?77+4?3 kPa and patients with mild
or moderate lung disease had significantly lower PCO2 than
patients with severe emphysema (4?56+0?48 and
4?65+1?28 kPa vs. 4?85+1?27 kPa, P50?001). A large
percentage of patients in group II and III were hypocapnic,
with PCO2 pressures of less than 4?67 kPa. PCO2 levels of
more than 6?0 kPa were only present in six out of 369
(1?6%) patients [Fig. 1(c)]. All but one of these patients had
severe impairment of FEV1. The FEV1 was a statistically
significant predictor for PCO2 values, indicating normocap-
nia, hypocapnia or hypercapnia (P50?001).
In the majority of cases, lung function data showed
moderately to severely impaired forced expiratoryTABLE 2. Data of pulmonary function tests of 369 patients w
function impairment (mean+SD)
Total % predicted FEV1 >65%
(group III)
VC [l] 3?6+1?2 84+21 4?7+1?3 10
FEV1 [l] 1?34+0?63 39+16 2?73+0?81 7
FEV1/VC 37+11 47+14 59+11 7
RV [l] 5?1+1?7 253+7 3?4+1?1 17
TLC [l] 8?4+2?3 130+30 7?8+1?8 11
RV/TLC 62+16 189+51 46+18 14
VC: vital capacity; FEV1: forced expiratory volume in 1 sec; Rvolume in 1 sec (FEV1), while vital capacity (VC) was
preserved. Hyperinflation was present in all groups; even
patients with FEV1 greater than 65% had a mean residual
volume (RV) of 173% of the predicted normal values
(Table 2).ith severe a1-Pi deficiency stratified for the severity of lung
FEV1 30–65%
(group II)
FEV1 530%
(group I)
7+17 3?8+1?1 90+16 3?1+1?0 69+17
7+11 1?43+0?37 43+8 0?85+0?21 24+4
4+14 39+8 49+10 29+7 36+9
3+57 4?7+1?3 236+56 6?0+1?9 299+86
9+14 8?1+2?2 128+28 8?9+2?6 135+34
2+61 60+15 180+50 69+12 214+37
V: residual volume; TLC: total lung capacity.
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Two hundred and eighty-two patients had complete
data collected on pulmonary function, and blood gas
analysis both at rest and during exercise for at least one
visit.
The pattern of PO2 change during exercise was different
depending on the FEV1. In the total group, more than 182
of 282 patients (65%) had a decrease of more than 0?40 kPa
[Fig. 2(a)]. Patients in group I showed a decline of PO2 more
frequently (73%) than patients in group II (63%) and 12
out of 26 patients (46%) with FEV1 greater than 65% had
decreasing PO2 values during exercise [Fig. 2(a)]. Also,
compared to PO2 at rest, mean values during exercise were
significantly lower (P50?0001) (Table 3). The FEV1 group
was a significant predictor for the PO2 concentration during
exercise (P50?005). The influence of the FEV1 group onFIG. 2. Changes of blood gases during submaximal
exercise after reaching respiratory steady state of 282
patients with a1-Pi deficiency. The change was labelled as
‘increase’ or ‘decrease’ if a change of more than 3mmHg
compared to resting values occurred. (a) change of PO2;
(b) change of AaDO2; (c) change of PCO2.the change of PO2 during exercise (DPO2) was of borderline
significance (P=0?07).
Almost half of the patients had an increase of PCO2
during exercise [Fig. 2(c)], which resulted in an increase in
the mean PCO2 of 0?32+0?47 kPa in the whole group.
Analysis of the data pairs before and during exercise
showed that this increase of PCO2 during exercise was
statistically significant (Wilcoxon matched-pairs,
P50?0005). Analysed in more detail, 76 of 134 patients
with initial hypocapnia stayed hypocapnic during exercise,
57 increased their low PCO2 to normal and one patient
became hypercapnic. While the majority of patients (115 of
146) with normal PCO2 at rest had no significant change
during exercise, 13 declined to hypocapnic levels and 18
increased to PCO2 values above 6 kPa. The two patients with
hypercapnia at rest remained hypercapnic with exercise.
The FEV1 group was a predictor for PCO2 concentrations
during exercise (P50?005) and the change of PCO2 during
exercise (P50?005).
Like the AaDO2 values at rest, AaDO2 levels during
exercise were elevated above 2?67 kPa in almost all
patients, normal values being present in only 16 patients.
The mean AaDO2 values analysed for the different FEV1
groups showed a slight increase with exercise in groups I
and II, whereas group III showed a decrease by 0?05 kPa
(Table 3).
The proportion of patients with increasing AaDO2 values
(approximately 50%) or decreasing AaDO2 values (approxi-
mately 25%) was similar in all groups. There was a
tendency towards a higher number of patients with
decreasing AaDO2 from high levels towards normal (i.e. a
reduction of ventilation–perfusion inequality) in patients
with well preserved lung function [Fig. 2(b)].
Both the AaDO2 during exercise and the change of
AaDO2 during exercise were independent of the FEV1
(r=0?46 and r=0?39, respectively, P=NS). The overall
increase during exercise was 0?29 kPa for all 282 patients
included in this cohort. This increase was statistically
significant (Wilcoxon matched-pairs test, P50?0001) and
the number of patients with increasing AaDO2 was higher
than those with unchanged or decreasing AaDO2 (
2-test,
P50?0005).
Forty-three of 60 patients with resting PO2 levels of more
than 10?0 kPa had a substantial decrease in PO2 during
exercise and the results were similar for patients with
moderate or severe hypoxaemia. There was no influence of
the resting values of PO2 and DPO2 during exercise on either
AaDO2 or DAaDO2 with exercise.
Discussion
To investigate the causes of hypoxaemia, multiple inert gas
elimination technique (MIGET) can give the most exact
estimation of ventilation–perfusion inequalities in vivo (22),
but the application of MIGET is not feasible in multi-
centre observational studies like the one presented here.
Arterial blood gases at rest and during exercise can give a
rough approximation of the causes of blood gas distur-
bances.
TABLE 3. Data of blood gases and AaDO2 at rest and during exercise of 282 patients with severe a1-Pi deficiency (mean+SD), as
well as the mean change during exercise (mean+SD).
Total FEV1465% FEV1 30–65% FEV1 530% P
Number of patients 282 26 178 78
PO2 at rest [kPa] 9?30+1?13 9?54+1?23 9?41+1?12 8?97+1?05 0?001
PO2 during exercise[kPa] 8?61+1?53 9?52+1?60 8?69+1?56 8?14+1?31 0?001
DPO2 [kPa] 70?72+1?40 70?16+1?19 70?73+1?53 70?88+1?12 0?07
PCO2 at rest [kPa] 4?73+0?49 4?56+0?44 4?65+0?48 4?96+0?49 0?001
PCO2 during exercise [kPa] 5?05+0?64 4?61+0?60 4?96+0?60 5?40+0?57 0?001
DPCO2 [kPa] 0?32+0?47 0?05+0?37 0?29+0?47 0?44+0?47 0?005
AaDO2 at rest [kPa] 4?65+1?24 4?63+1?60 4?63+1?24 4?71+1?13 NS
AaDO2 during exercise [kPa] 4?95+1?57 4?57+1?93 4?97+1?59 4?97+1?41 NS
DAaDO2 [kPa] 0?29+1?41 70?05+1?40 0?35+1?49 0?27+1?20 NS
AaDO2: arterio–alveolar oxygen gradient; D: difference between resting and exercise values.
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Few data on the blood gases of patients with a1-Pi are
available in the literature. Among published studies, the
number of patients investigated were generally so small that
the influence of lung function on the blood gases were not
analysed (1,8,11,23). Most authors only report mean values
of all patients tested with PO2 at rest showing mild to
moderate hypoxaemia. In the three studies presenting
individual data, the scattering of PO2 values at rest was
considerable (5,10,12). Only few patients with hypercapnia
at rest were found, and, if data on FEV1 were given, they
were always associated with severely impaired FEV1
(10,11,23,24).
Our data demonstrate that mild-to-moderate hypoxae-
mia is present in 80% of all tested patients with a1-Pi
deficiency and in 60% of patients with only mild lung
disease and the lung function impairment. The number of
patients with hypoxaemia increases and the severity of
hypoxaemia worsens with increasing lung function impair-
ment; FEV1 is a significant predictor for the PO2 at rest.
These results are in agreement with the findings of Levine
et al. (18). Their study showed reduced PO2 levels at rest in
mild COPD patients with normal lung function values
compared to normal patients (95?0+1?44 vs.
83?4+1?66mmHg equivalent to 12?66+0?19 vs.
11?12+0?22 kPa, P50?005). In contrast with the Levine
study, however, in our patients, the extent of hypoxaemia
even in patients with FEV1 greater than 65% was more
pronounced. Moreover, in our study, AaDO2 showed even
more pathological changes since a large percentage of
patients in group II and III were hypocapnic at rest. Only
13% of patients had normal AaDO2 values at rest. Thus,
alveolar hyperventilation may mask hypoxaemia at least
partially. Using only oxymetry, the degree of gas exchange
disturbances in the lungs would be underestimated.
While impaired blood gases at rest can also be found in
mild COPD (18), we were surprised by the high prevalence
and degree of hypoxaemia in patients with a1-Pi deficiency
and mild lung disease. In addition, we did not expect thevery high percentage of pathologically increased AaDO2 at
rest in the whole group.
Since the PCO2 levels at rest were normal or reduced in most
patients, alveolar hypoventilation can be ruled out as the
cause for decreased PO2.
CHANGE OF BLOOD GASES DURING
EXERCISE
Similar to the classic study in patients with severe COPD by
Jones (25), we could demonstrate a significant decline in
PO2 during exercise in some patients with a1-Pi deficiency;
in others, we found an increase in PO2. These opposite
responses to exercise in patients with COPD were explained
by different degrees of venous admixture reflected by
AaDO2 values. Patients with increasing AaDO2 during
exercise failed to decrease their venous admixture (26).
The reason for decreasing PO2 may be either (a) V/Q
mismatch; (b) alveolar hypoventilation due to ventilation
limitation; or (c) diffusion impairment due to emphysema
or bronchiolitis. Even though simple blood gas analysis at
rest and during exercise is less accurate than breath-to-
breath analysis, the former method still allows a crude
estimation of the underlying causes of hypoxaemia.
Assuming a single cause for resting hypoxaemia: (a)
ventilation–perfusion inequalities are associated with an
increase of PO2 and a decrease of AaDO2 during exercise if
the V/Q mismatch is reduced; (b) inability to increase the
minute ventilation is associated with a decrease in PO2, an
increase in PCO2, and unchanged AaDO2; (c) diffusion
impairment is associated with a decrease in PO2, an increase
in AaDO2 and unchanged PCO2.
All of these mechanisms were found in the patients
studied. About 20% of the patients with a1-Pi deficiency
had increasing PO2 and decreasing AaDO2 values during
exercise, indicating a V/Q mismatch as the cause for the
resting hypoxaemia. Thirty-five per cent had increasing
PCO2 and decreasing PO2 values with unchanged AaDO2.
This may be due to this cohort’s inability to further increase
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the psyche as a cause of hyperventilation at rest. Twenty-
five per cent had a worsening of PO2 and AaDO2 because of
either diffusion impairment or increased V/Q mismatch.
COPD patients usually show no evidence for diffusion
limitation on exercise test despite reduced diffusion
capacity. This is because these individuals have more
pronounced ventilation impairment as a result of airflow
obstruction (22). However, more than 60% of the patients
with a1-Pi deficiency dropped their PO2 during steady state
exercise. With the methods applied we cannot differentiate
diffusion impairment from worsened V/Q mismatch as the
cause of falling PO2 during exercise. However, since
emphysema is present in these patients as can readily be
shown by pathological (27) and CT-studies (28), diffusion
impairment may play a role in these patients. Even though
the presence of anatomic shunting or cardiac disease in
these patients cannot be ruled out entirely on the basis of
the data available, it is more than unlikely that these factors
contributed in the decline of PO2 in the majority of patients.
As in COPD without a1-Pi deficiency, patients with a1-Pi
deficiency have blood gas alterations that may precede
other changes in lung function and as in COPD without a1-
Pi deficiency: PO2 may increase, decrease or remain
unchanged. There is no distinct pattern in the change of
blood gases at rest or during exercise for the different
degrees of lung function impairment in patients with a1-Pi
deficiency. Neither lung function tests nor blood gas
measurements offer sensitive assessment of early COPD
regardless of whether the COPD is smoking-related or
genetically-associated. The discrepancies between lung
function parameters and measurements of blood gases,
whether taken when the patient is resting or exercising, may
add to the under-recognition of a1-Pi deficiency. In addition
to PFTs, blood gas analysis at rest is needed because PFTs
do not predict alterations in gas exchange. Moreover, blood
gases must also be measured during exercise, because
resting values are no predictor for individual changes that
occur during exercise.
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